Globe Life’s third quarter saw solid revenue growth, yet the market responded negatively after adjusted earnings came in below analyst expectations. Management pointed to operational headwinds in its United American General Agency Division, most notably due to a process change at the Centers for Medicare & Medicaid Services (CMS) that led to elevated claims. Additionally, the Evri group health business experienced higher-than-expected severity in claims, contributing to lower underwriting margins. Co-CEO Frank Martin Svoboda acknowledged, “Underwriting results this quarter were adversely impacted by a process change at CMS…and high severity claims at Evri.”
Is now the time to buy GL? Find out in our full research report (it’s free for active Edge members).
Globe Life (GL) Q3 2026 highlights:
- Revenue: $1.61 billion vs analyst estimates of $1.61 billion (6% year-on-year growth, in line)
- Adjusted EPS: $4.84 vs analyst expectations of $4.89 (1.1% miss)
- Market Capitalization: $12.94 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Globe Life’s Q3 earnings call
-
Ryan Krueger (KBW) asked how much assumption review benefit was embedded in the 2027 EPS guidance. CFO Thomas Peter Kalmbach said the ranges incorporate multiple scenarios and actual results in the coming quarters will clarify the impact.
-
Wilma Burdis (Raymond James) pressed for more detail on Evri’s financial impact and long-term strategic fit. Co-CEO James Matthew Darden emphasized the need for scale to stabilize volatility and said the division’s contribution to overall health margins would remain limited.
-
Randy Binner (Texas Capital) inquired about the CMS claims delay and its resolution. Kalmbach explained that new Medicare IDs and billing corrections drove the Q3 spike, and expects normalization going forward.
-
Andrew Kligerman (TD Cowen) questioned management’s confidence in projected agent-driven sales growth, given recent declines in agent count. Darden cited recent compensation changes and stabilized agent numbers as reasons for optimism about future sales.
-
Tom Gallagher (Evercore ISI) asked how Globe Life would avoid persistent high-severity claims in Evri. Darden outlined strict underwriting discipline, turning down over 70% of cases, and indicated growth will be constrained until credible scale is achieved.
Catalysts in upcoming quarters
Looking ahead, the StockStory team will be monitoring (1) the stabilization of group health margins at Evri as pricing changes and scale develop, (2) progress in agent recruiting and productivity across major channels, and (3) continued adaptation to digital marketing trends in the Direct to Consumer business. Additionally, we will track the pace and regulatory approval of reinsurance transactions with the Bermuda subsidiary and their impact on capital flexibility.
Globe Life currently trades at $171.54, up from $169.62 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
High-quality stocks for all market conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
